Under the deal, France-based Sanofi SA plans on buying all of the outstanding shares of the Massachusetts-based company's common stock for $105 per... To view the full article, register now.
Eyelea U.S. sales and sales of Praluent and Dupixent, two collaborations between Regeneron and Sanofi SNY, -4.08% beat the FactSet consensus. Arcalyst sales matched the consensus and sales of Kevzara and Zaltrap, which are also …
Paris - February 8, 2018 - Sanofi announced today that on February 7, 2018 it commenced a tender offer (the "Offer") to acquire all of the outstanding shares of common stock of Bioverativ, Inc. ("Bioverativ") for $105 per share in cash (the …
Sanofi SA (SAN.FR) said on Wednesday that fourth-quarter net profit decreased significantly due in part to a drop in sales and a tax-related charge. The French …
(RTTNews) - French drug giant Sanofi SA (SNYNF, SNY) announced Thursday it commenced a tender offer on Wednesday to acquire all of the outstanding shares of common stock of Bioverativ, Inc. (BIVV) for $105 per share in …
02/09 After two high-profile M&A fails, how did Sanofi win Bioverativ? 02/09 Bioverativ execs haul in new fortunes after patiently waiting for Sanofi to b.. 02/09 Bioverativ execs haul in new fortunes after patiently waiting for Sanofi to b..
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing …
Sanofi SA (ADR) (NYSE:SNY) is the world’s No. 5 pharmaceutical company. It has over 100 manufacturing sites in 41 countries and has 110,000 employees in 100 countries. Its five top divisions do $40 billion in sales every year, and it …